Comments
Aurobindo Pharma has received the US health regulator’s nod to manufacture and market Fosinopril Sodium tablets, used for the treatment of hypertension, in the American market.
The approval from the United States Food and Drug Administration is for Fosinopril Sodium tablets USP in strengths of 10 mg, 20 mg and 40 mg, Aurobindo Pharma said in a filing to the Bombay Stock Exchange today.
“The product has a market size of approximately $20 million for the 12 months ending September, 2010, according to IMS, and will be launched shortly,” the company said.
The tablets are generic versions of the Monopril tablets of global biopharmaceutical company Bristol-Myers Squibb in the same strengths and fall under the cardiovascular (CVS) therapeutic category.
Meanwhile, the shares of Aurobindo Pharma were being quoted at Rs 193.65 apiece in the afternoon trade on the BSE today, down 0.08 per cent from their previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.